Journal: Cell death discovery
Article Title: CO confers neuroprotection via activating the PERK-calcineurin pathway and inhibiting necroptosis.
doi: 10.1038/s41420-025-02530-9
Figure Lengend Snippet: Fig. 6 Regulation of GSK-3β and PERK by CO sustain nuclear TFEB levels, leading to suppressed amyloidogenesis. a–d SH-SY5Y cells were treated with 20 μM CORM-A1 after the cells were transfected with CA-GSK-3β or treated with 1 μM GSK2606414. Nuclear and cytoplasmic fractions extracted from SH-SY5Y cells were analyzed by western blotting using TFEB antibody (left), and quantification of nuclear TFEB and cytosol TFEB was analyzed (right) (a). The levels of p-GS, GS, p-eIF2α, and eIF2α expression were assessed by western blotting (b). Quantification of p-GS and p-eIF2α (c). The protein expression of autophagy protein LC3-I/-II and lysosomal protein LAMP1 was detected by western blotting (left panel) (d), and quantification of LC3-II conversion and LAMP1 is shown in the right panels. e SH-SY5Y cells were transfected with APP-Swe/Ind and then treated with 20 μM CORM-A1 for 12 h in the presence or absence of 1 μM GSK2606414. The levels of APP, LAMP1, LC3-I/-II, p-eIF2α, and eIF2α expression were detected by western blotting. f SH-SY5Y cells were co-transfected with APP-Swe/Ind and siTfeb for 36 h and were treated with 20 μM CORM-A1 for 12 h. The levels of APP, LAMP1, LC3-I/-II, and TFEB were analyzed by western blotting. g SH-SY5Y cells were treated with 20 μM CORM-A1 after the cells were co-transfected with CA-GSK-3β and APP-Swe/Ind or treated with 1 μM GSK2606414. The protein expression of FL-APP was determined by western blotting (left), and quantification of FL-APP was analyzed (right). Data were expressed as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001, and NS not significant.
Article Snippet: To knockdown mRNA levels of TFEB, GSK-3β, PERK, BECN-1, and PP2BAα, SHSY5Y cells were transfected with siRNA against TFEB, GSK-3β, PERK, BECN-1, and PP2BAα (Santa Cruz, CA, USA), or with scramble siRNA (scRNA) (Ambion, Austin, TX, USA) as the control, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s protocol. α-syn-A53T, pCAX-APP-Swe/Ind, pEGFP-N1-TFEB, pcDNA3.1, pcDNA3.1GSK-3β-S9A, and pcDNA3.1-GSK-3β-K85A, and hMLKL-Venus were from Addgene (Watertown, MA, USA) and were transfected into cells via Lipofectamine 2000 (Invitrogen). qRT-PCR Total RNA from cells and midbrain tissues was isolated by QIAzol Lysis reagent (QIAGEN, Valencia, CA, USA).
Techniques: Transfection, Western Blot, Expressing